Hasti Kamali Sarvestani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Hasti Kamali Sarvestani has a total of 71 co-authors. Here are the top co-authors by number of shared publications:
Fuad Haghighat
Department of Medical Parasitology and Mycology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
3 shared publicationsAbbas Rahimi Foroushani
Department of Epidemiology and Biostatistics, School of Health, Tehran University of Medical Sciences, Tehran, Iran
2 shared publicationsMahmoud Khansari
2 shared publicationsShahram Mahmoudi
2 shared publicationsZahra Rafat
Department of Medical Parasitology and Mycology, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran
2 shared publications- Abdollah Rafiei
Infectious and Tropical Diseases Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
1 shared publication
Latest Publications
- 16 May 2026
- Published by Elsevier in Microbial Pathogenesis
- Vol. 217, 108558
Breaking the treatment barrier in Trichophyton indotineae and related species: A systematic review of case reports and case series
- 16 May 2026
- Published by Elsevier in Microbial Pathogenesis
- Vol. 217, 108558
Breaking the treatment barrier in Trichophyton indotineae and related species: A systematic review of case reports and case series
- Open Access
- 19 February 2026
- Published by Pensoft Publishers in IMA Fungus
- Vol. 17
Dermatophytosis in Iran: a sharp increase in cases caused by Trichophyton mentagrophytes var. indotineae
Dermatophytosis is a common skin infection worldwide. In recent years, Trichophyton mentagrophytes var. indotineae has rapidly emerged as a leading cause of recalcitrant dermatophytosis. Iran shows high genetic diversity within the T. mentagrophytes complex, suggesting local emergence of new genotypes, yet nationwide data remain limited. We performed a one-year multicentre, hospital-based survey of referred cases (September 2023–September 2024) in nine provinces of Iran to describe the current epidemiology of dermatophytosis and to analyse mutations in the squalene epoxidase (SQLE) gene associated with terbinafine (TRB) resistance. Clinical samples were obtained from 2211 patients with suspected dermatophytosis. Dermatophytes were recovered from 1568 samples (71%). Species-specific PCR identified T. mentagrophytes var. indotineae in 1191 cases (76%), confirming it as the dominant agent across all clinical forms, age groups and provinces. The remaining isolates comprised other dermatophytes, mainly other members of the T. mentagrophytes complex, T. tonsurans and Microsporum canis . Trichophyton mentagrophytes var. indotineae caused most cases of tinea cruris, tinea corporis, mixed infections and generalised dermatophytosis. It also accounted for 59% of tinea unguium and 37% of tinea capitis cases. No significant sex bias was observed and most patients were 20–49 years old. The data did not indicate recent introduction of the infection from outside Iran, supporting ongoing local transmission. SQLE sequencing of 410 isolates revealed resistance-associated mutations in 45% of strains, mainly F397L (72%) and L393S (28%), with the highest frequencies in southern provinces. ITS sequencing of a subset of isolates confirmed their identity as T. indotineae and revealed two ITS genotypes, including a dominant genotype VIII and a new sub-genotype XXIX. These findings show that T. indotineae is now the dominant dermatophyte in Iran and carries a substantial burden of SQLE mutations, highlighting the urgent need for continued molecular surveillance and antifungal stewardship.
- 19 February 2026
- Published by Pensoft Publishers in IMA Fungus
- Vol. 17
Open AccessDermatophytosis in Iran: a sharp increase in cases caused by Trichophyton mentagrophytes var. indotineae
Dermatophytosis is a common skin infection worldwide. In recent years, Trichophyton mentagrophytes var. indotineae has rapidly emerged as a leading cause of recalcitrant dermatophytosis. Iran shows high genetic diversity within the T. mentagrophytes complex, suggesting local emergence of new genotypes, yet nationwide data remain limited. We performed a one-year multicentre, hospital-based survey of referred cases (September 2023–September 2024) in nine provinces of Iran to describe the current epidemiology of dermatophytosis and to analyse mutations in the squalene epoxidase (SQLE) gene associated with terbinafine (TRB) resistance. Clinical samples were obtained from 2211 patients with suspected dermatophytosis. Dermatophytes were recovered from 1568 samples (71%). Species-specific PCR identified T. mentagrophytes var. indotineae in 1191 cases (76%), confirming it as the dominant agent across all clinical forms, age groups and provinces. The remaining isolates comprised other dermatophytes, mainly other members of the T. mentagrophytes complex, T. tonsurans and Microsporum canis . Trichophyton mentagrophytes var. indotineae caused most cases of tinea cruris, tinea corporis, mixed infections and generalised dermatophytosis. It also accounted for 59% of tinea unguium and 37% of tinea capitis cases. No significant sex bias was observed and most patients were 20–49 years old. The data did not indicate recent introduction of the infection from outside Iran, supporting ongoing local transmission. SQLE sequencing of 410 isolates revealed resistance-associated mutations in 45% of strains, mainly F397L (72%) and L393S (28%), with the highest frequencies in southern provinces. ITS sequencing of a subset of isolates confirmed their identity as T. indotineae and revealed two ITS genotypes, including a dominant genotype VIII and a new sub-genotype XXIX. These findings show that T. indotineae is now the dominant dermatophyte in Iran and carries a substantial burden of SQLE mutations, highlighting the urgent need for continued molecular surveillance and antifungal stewardship.
- Top Cited Papers
- 7 January 2026
- Published by Elsevier in Microbial Pathogenesis
- Vol. 212, 108284
Vulvovaginal candidiasis: A global perspective through systematic review and meta-analysis
- 7 January 2026
- Published by Elsevier in Microbial Pathogenesis
- Vol. 212, 108284
Top Cited PapersVulvovaginal candidiasis: A global perspective through systematic review and meta-analysis
- 13 December 2025
- Published by Springer Nature in Lasers in Medical Science
- Vol. 40 (1) , 523
Harnessing nd: YAG laser technology to combat antifungal resistance in yeast-driven onychomycosis
Onychomycosis is a persistent nail infection often caused by dermatophytes or yeasts, with conventional treatments limited by long durations, poor compliance, and resistance. The long-pulsed Nd: YAG 1064 nm laser (NDYL) has emerged as a potential adjunct; however, its effects in combination with antifungals against yeast-related cases are unclear. This study examined the in vitro synergistic effect of NDYL with four antifungal agents—Ketoconazole (KET), Itraconazole (ITK), Voriconazole (VRC), and Terbinafine(TRB)—on clinical yeasts isolates from patients with onychomycosis. Yeast isolates were identified through ITS PCR sequencing. Susceptibility testing was conducted using the CLSI disk diffusion method (document M44-A2). Two experimental series—vital nail scrapings and cultured colonies—were exposed to standardized NDYL laser parameters. Antifungal activity was assessed by measuring inhibition zone diameters, and statistical comparisons were performed using paired t-tests. NDYL significantly enhanced antifungal activity, with the most pronounced effects observed for KET and ITC (p < 0.05). KET achieved up to 100% sensitivity improvement in nail scraping samples. VRC and TRB demonstrated moderate but consistent enhancements. Recorded irradiation temperatures remained below 42 °C, suggesting primarily non-thermal mechanisms. The relative frequencies of increased inhibition zone diameters in nail scrapings, yeast colonies, and combined datasets were: ITC (83.3%, 50.0%, 66.7%), VRC (66.7%, 50.0%, 58.3%), TRB (33.3%, 16.7%, 25.0%), and KET (100%, 66.7%, 83.3%). These findings support NDYL as a potential adjunctive tool for enhancing antifungal efficacy in yeast-associated onychomycosis. Further in vivo research is warranted to confirm clinical applicability and refine treatment protocols.
- 13 December 2025
- Published by Springer Nature in Lasers in Medical Science
- Vol. 40 (1) , 523
Harnessing nd: YAG laser technology to combat antifungal resistance in yeast-driven onychomycosis
Onychomycosis is a persistent nail infection often caused by dermatophytes or yeasts, with conventional treatments limited by long durations, poor compliance, and resistance. The long-pulsed Nd: YAG 1064 nm laser (NDYL) has emerged as a potential adjunct; however, its effects in combination with antifungals against yeast-related cases are unclear. This study examined the in vitro synergistic effect of NDYL with four antifungal agents—Ketoconazole (KET), Itraconazole (ITK), Voriconazole (VRC), and Terbinafine(TRB)—on clinical yeasts isolates from patients with onychomycosis. Yeast isolates were identified through ITS PCR sequencing. Susceptibility testing was conducted using the CLSI disk diffusion method (document M44-A2). Two experimental series—vital nail scrapings and cultured colonies—were exposed to standardized NDYL laser parameters. Antifungal activity was assessed by measuring inhibition zone diameters, and statistical comparisons were performed using paired t-tests. NDYL significantly enhanced antifungal activity, with the most pronounced effects observed for KET and ITC (p < 0.05). KET achieved up to 100% sensitivity improvement in nail scraping samples. VRC and TRB demonstrated moderate but consistent enhancements. Recorded irradiation temperatures remained below 42 °C, suggesting primarily non-thermal mechanisms. The relative frequencies of increased inhibition zone diameters in nail scrapings, yeast colonies, and combined datasets were: ITC (83.3%, 50.0%, 66.7%), VRC (66.7%, 50.0%, 58.3%), TRB (33.3%, 16.7%, 25.0%), and KET (100%, 66.7%, 83.3%). These findings support NDYL as a potential adjunctive tool for enhancing antifungal efficacy in yeast-associated onychomycosis. Further in vivo research is warranted to confirm clinical applicability and refine treatment protocols.
- 26 July 2025
- Published by Springer Nature in Molecular Biotechnology
- Vol. 68 (4) , 1921-1928
Nanoemulsion-Based Tea Tree Oil: A New Frontier in Enhancing Clotrimazole Antifungal Activity
Clotrimazole is widely used to treat fungal diseases, but it should be applied topically for several weeks to be effective. Previous studies have shown that nanoemulsions can enhance the topical activity of various active ingredients. This study aimed to prepare a nanoformulation of clotrimazole to improve its antifungal activity. A nanoemulsion containing clotrimazole was prepared using Tween 80 and Tween 20. The particle size was measured using Dynamic Light Scattering (DLS) and Transmission Electron Microscopy (TEM). Stability studies were conducted using freeze–thaw cycles and storage at 40 °C. The antifungal activity of clotrimazole was then compared with bulk clotrimazole both in vitro and in vivo. The nanoemulsion containing clotrimazole had a particle size of 31.5 nm, measured by DLS and remained physically stable after 1 year of storage. In vitro antifungal studies showed that this nanoemulsion outperformed both bulk clotrimazole and the nanoemulsion without clotrimazole, with MIC values of 1/524288, 1/8192, and 1/1024, respectively, against T. mentagrophytes. In addition, animal studies demonstrated that mean (SD) treatment time for fungal infection was 8.6 (0.5) days with the nanoemulsion containing 1% clotrimazole, significantly smaller than that of bulk clotrimazole (1% w/w) and nanoemulsion without clotrimazole (i.e., 15.0 (1.6) and 20.0 (0.7) days, respectively). The treatment time was more than 21 days for the bulk tea tree oil and the untreated control. After 21 days of treatment, only animals treated with the clotrimazole nanoemulsion showed complete lesion healing and weight changes comparable to healthy animals. The nanoemulsion formulation containing clotrimazole demonstrates highly desirable antifungal properties, warranting further investigation in clinical trials.
- 26 July 2025
- Published by Springer Nature in Molecular Biotechnology
- Vol. 68 (4) , 1921-1928
Nanoemulsion-Based Tea Tree Oil: A New Frontier in Enhancing Clotrimazole Antifungal Activity
Clotrimazole is widely used to treat fungal diseases, but it should be applied topically for several weeks to be effective. Previous studies have shown that nanoemulsions can enhance the topical activity of various active ingredients. This study aimed to prepare a nanoformulation of clotrimazole to improve its antifungal activity. A nanoemulsion containing clotrimazole was prepared using Tween 80 and Tween 20. The particle size was measured using Dynamic Light Scattering (DLS) and Transmission Electron Microscopy (TEM). Stability studies were conducted using freeze–thaw cycles and storage at 40 °C. The antifungal activity of clotrimazole was then compared with bulk clotrimazole both in vitro and in vivo. The nanoemulsion containing clotrimazole had a particle size of 31.5 nm, measured by DLS and remained physically stable after 1 year of storage. In vitro antifungal studies showed that this nanoemulsion outperformed both bulk clotrimazole and the nanoemulsion without clotrimazole, with MIC values of 1/524288, 1/8192, and 1/1024, respectively, against T. mentagrophytes. In addition, animal studies demonstrated that mean (SD) treatment time for fungal infection was 8.6 (0.5) days with the nanoemulsion containing 1% clotrimazole, significantly smaller than that of bulk clotrimazole (1% w/w) and nanoemulsion without clotrimazole (i.e., 15.0 (1.6) and 20.0 (0.7) days, respectively). The treatment time was more than 21 days for the bulk tea tree oil and the untreated control. After 21 days of treatment, only animals treated with the clotrimazole nanoemulsion showed complete lesion healing and weight changes comparable to healthy animals. The nanoemulsion formulation containing clotrimazole demonstrates highly desirable antifungal properties, warranting further investigation in clinical trials.
- Open Access
- 16 July 2024
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 11, 1396224
Chromoblastomycosis caused by Alternaria infectoria, concurrent with myiasis, in a recipient of a kidney transplant: a compelling case report
Neglected tropical diseases (NTDs) pose a significant threat to the health of millions of people worldwide, particularly in impoverished populations in tropical and subtropical regions. The World Health Organization (WHO) considers certain fungal infections, such as chromoblastomycosis, as NTDs. Chromoblastomycosis is a chronic fungal infection affecting the skin and subcutaneous tissue, primarily found in tropical and subtropical regions of Latin America, Africa, and Asia. This case report presents a 46-year-old female patient with chromoblastomycosis who had a history of renal transplantation and was receiving immunosuppressive therapy. The patient exhibited dark, verrucous, and ulcerative lesions on the legs, and the diagnosis was confirmed through the microscopic examination of skin scrapings by observing medlar bodies. Two sequential fungal tissue cultures and ITS sequencing verified the presence of Alternaria infectoria, not formerly described in chromoblastomycosis. Moreover, observation of fly larvae in the lesions verified the diagnosis of myiasis. Treatment with voriconazole and terbinafine resulted in complete resolution of the lesions after 5 months. This case emphasizes the importance of considering chromoblastomycosis in individuals with occupational exposure in tropical areas, as well as the challenges associated with its diagnosis, coinfections, and treatment.
- 16 July 2024
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 11, 1396224
Open AccessChromoblastomycosis caused by Alternaria infectoria, concurrent with myiasis, in a recipient of a kidney transplant: a compelling case report
Neglected tropical diseases (NTDs) pose a significant threat to the health of millions of people worldwide, particularly in impoverished populations in tropical and subtropical regions. The World Health Organization (WHO) considers certain fungal infections, such as chromoblastomycosis, as NTDs. Chromoblastomycosis is a chronic fungal infection affecting the skin and subcutaneous tissue, primarily found in tropical and subtropical regions of Latin America, Africa, and Asia. This case report presents a 46-year-old female patient with chromoblastomycosis who had a history of renal transplantation and was receiving immunosuppressive therapy. The patient exhibited dark, verrucous, and ulcerative lesions on the legs, and the diagnosis was confirmed through the microscopic examination of skin scrapings by observing medlar bodies. Two sequential fungal tissue cultures and ITS sequencing verified the presence of Alternaria infectoria, not formerly described in chromoblastomycosis. Moreover, observation of fly larvae in the lesions verified the diagnosis of myiasis. Treatment with voriconazole and terbinafine resulted in complete resolution of the lesions after 5 months. This case emphasizes the importance of considering chromoblastomycosis in individuals with occupational exposure in tropical areas, as well as the challenges associated with its diagnosis, coinfections, and treatment.
- Open Access
- 9 February 2024
- Published by Brieflands in Jundishapur Journal of Microbiology
- Vol. 16 (12)
Clinical Characteristics of Patients with Hematologic Malignancies and Invasive Aspergillosis: A Cross-sectional Clinical Report from Iran
Background: The incidence of invasive aspergillosis (IA) has significantly increased in recent decades. In patients with hematologic malignancies (HM), IA is associated with higher mortality rates. Objectives: This study aimed to assess the clinical features of IA in patients with HM. Methods: In this retrospective study, we used the hospital information system (HIS) database to extract clinical and paraclinical characteristics of patients with various HMs who received a diagnosis of probable or proven IA during their hospitalization at Imam Khomeini Hospital Complex in Tehran, Iran, between March 2018 and March 2022. Results: After evaluating 350 patients with HM, 51 patients with IA (14.6%) were identified, of whom 40 cases (78.4%) were probable and 11 (21.6%) were proven. Among these, 34 individuals (66.7%) were male. The most common symptoms were fever (n = 23, 62.7%), cough (n = 20, 39.2%), and fever that did not respond to antibiotic therapy (n = 16, 31.4%). The most prevalent malignancies were AML (n = 28, 54.9%), ALL (n = 16, 31.4%), and lymphoma (n = 7, 13.7%). Out of the 51 patients with HM and IA, 48 (94.1%) had abnormal findings on chest CT scans, with the majority (n = 31, 72.1%) showing a nodule with a halo sign. Aspergillus flavus (n = 19/24, 79.2%) was the most commonly isolated species. Initially, patients received liposomal amphotericin B or caspofungin as empiric antifungal therapy, which was then switched to voriconazole once the diagnosis of IA was probable or proven. Eight patients (15.6%) died. Conclusions: Patients with HM presenting with fever and cough should undergo close monitoring for IA. A higher incidence of IA is observed in AML patients, and voriconazole could be considered as antifungal prophylaxis in HM patients. A. flavus is likely the most frequent cause of IA in Iranian patients with HM.
- 9 February 2024
- Published by Brieflands in Jundishapur Journal of Microbiology
- Vol. 16 (12)
Open AccessClinical Characteristics of Patients with Hematologic Malignancies and Invasive Aspergillosis: A Cross-sectional Clinical Report from Iran
Background: The incidence of invasive aspergillosis (IA) has significantly increased in recent decades. In patients with hematologic malignancies (HM), IA is associated with higher mortality rates. Objectives: This study aimed to assess the clinical features of IA in patients with HM. Methods: In this retrospective study, we used the hospital information system (HIS) database to extract clinical and paraclinical characteristics of patients with various HMs who received a diagnosis of probable or proven IA during their hospitalization at Imam Khomeini Hospital Complex in Tehran, Iran, between March 2018 and March 2022. Results: After evaluating 350 patients with HM, 51 patients with IA (14.6%) were identified, of whom 40 cases (78.4%) were probable and 11 (21.6%) were proven. Among these, 34 individuals (66.7%) were male. The most common symptoms were fever (n = 23, 62.7%), cough (n = 20, 39.2%), and fever that did not respond to antibiotic therapy (n = 16, 31.4%). The most prevalent malignancies were AML (n = 28, 54.9%), ALL (n = 16, 31.4%), and lymphoma (n = 7, 13.7%). Out of the 51 patients with HM and IA, 48 (94.1%) had abnormal findings on chest CT scans, with the majority (n = 31, 72.1%) showing a nodule with a halo sign. Aspergillus flavus (n = 19/24, 79.2%) was the most commonly isolated species. Initially, patients received liposomal amphotericin B or caspofungin as empiric antifungal therapy, which was then switched to voriconazole once the diagnosis of IA was probable or proven. Eight patients (15.6%) died. Conclusions: Patients with HM presenting with fever and cough should undergo close monitoring for IA. A higher incidence of IA is observed in AML patients, and voriconazole could be considered as antifungal prophylaxis in HM patients. A. flavus is likely the most frequent cause of IA in Iranian patients with HM.
- Open Access
- 28 January 2022
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 8, 803600
The Value of Nasal and Oral Clinical Examination in Febrile Neutropenic Patients for Initiating Antifungal Therapy as a Preemptive Method
Background: Invasive fungal infections (IFIs) are complications that lead to mortality and morbidity in hematologic malignancies. The time of starting antifungal therapy is vital. Preemptive antifungal therapy has appeared recently as a new policy for the management of IFIs based on noninvasive ways in neutropenic patients.Methods: We enrolled leukemia patients with neutropenia after chemotherapy in Imam Khomeini Hospital Complex, Tehran, Iran. Patients who entered the neutropenic phase were divided into two categories (empirical and preemptive) for receiving antifungal agents. The patients were clinically examined in the preemptive group every day to find IFIs. As soon as clinical evidence of IFIs was observed, antifungal was prescribed. The empirical group patients received antifungals based on the ward protocol. Based on the data in each group, the diagnostic and therapeutic results of cases are followed-up to 3 months. To compare percentages between the two groups, the chi-squared test was used. And to compare two means between the two groups, the independent t-test was used. All the statistical analyses were done in the Statistical Package for the Social Sciences (SPSS) version 24 software (IBM Corporation, Armonk, New York, USA).Results: We assessed 132 leukemic patients with inclusion and exclusion criteria. Eventually, 80 patients were enrolled. The mean age was 35.52 years. Demographics data and distribution of leukemia type show no significant differences between the two groups. Despite a higher percentage of IFIs discovered in the preemptive group than the empirical group (25 vs. 18.75%, respectively), but data show no significant differences. The average days of IFIs diagnosis since the beginning of neutropenia in the empirical group were 9.5 days while in the preemptive group, the average days were 5.4 days (p < 0.05). Totally, there were 15 patients with a proven IFI in each group (40% in the empirical group and 60% in the preemptive group). Results significantly show an increase in surgical sinus debridement in the empirical groups (83.3%) vs. the preemptive groups (55.5%), (p < 0.05). The mortality rate differed significantly among the two groups; it was 7.5% in the preemptive group and 25% in the empirical group (p < 0.05).Conclusion: Daily oral and nasal cavities examination to find the symptoms of IFIs and then start preemptive antifungal agents may be able to lead to accurate diagnosis, earlier treatment, and decreasing sinus surgery debridement in leukemia patients with neutropenia.
- 28 January 2022
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 8, 803600
Open AccessThe Value of Nasal and Oral Clinical Examination in Febrile Neutropenic Patients for Initiating Antifungal Therapy as a Preemptive Method
Background: Invasive fungal infections (IFIs) are complications that lead to mortality and morbidity in hematologic malignancies. The time of starting antifungal therapy is vital. Preemptive antifungal therapy has appeared recently as a new policy for the management of IFIs based on noninvasive ways in neutropenic patients.Methods: We enrolled leukemia patients with neutropenia after chemotherapy in Imam Khomeini Hospital Complex, Tehran, Iran. Patients who entered the neutropenic phase were divided into two categories (empirical and preemptive) for receiving antifungal agents. The patients were clinically examined in the preemptive group every day to find IFIs. As soon as clinical evidence of IFIs was observed, antifungal was prescribed. The empirical group patients received antifungals based on the ward protocol. Based on the data in each group, the diagnostic and therapeutic results of cases are followed-up to 3 months. To compare percentages between the two groups, the chi-squared test was used. And to compare two means between the two groups, the independent t-test was used. All the statistical analyses were done in the Statistical Package for the Social Sciences (SPSS) version 24 software (IBM Corporation, Armonk, New York, USA).Results: We assessed 132 leukemic patients with inclusion and exclusion criteria. Eventually, 80 patients were enrolled. The mean age was 35.52 years. Demographics data and distribution of leukemia type show no significant differences between the two groups. Despite a higher percentage of IFIs discovered in the preemptive group than the empirical group (25 vs. 18.75%, respectively), but data show no significant differences. The average days of IFIs diagnosis since the beginning of neutropenia in the empirical group were 9.5 days while in the preemptive group, the average days were 5.4 days (p < 0.05). Totally, there were 15 patients with a proven IFI in each group (40% in the empirical group and 60% in the preemptive group). Results significantly show an increase in surgical sinus debridement in the empirical groups (83.3%) vs. the preemptive groups (55.5%), (p < 0.05). The mortality rate differed significantly among the two groups; it was 7.5% in the preemptive group and 25% in the empirical group (p < 0.05).Conclusion: Daily oral and nasal cavities examination to find the symptoms of IFIs and then start preemptive antifungal agents may be able to lead to accurate diagnosis, earlier treatment, and decreasing sinus surgery debridement in leukemia patients with neutropenia.